Navigation Links
BioMarin Receives Notice of Allowance for Once Daily Dosing Patent for Kuvan
Date:3/30/2009

NOVATO, Calif., March 30 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has received a notice from the United States Patent Office reporting allowance of claims covering once daily dosing methods for Kuvan(R) (sapropterin dihydrochloride) in the treatment of phenylketonuria (PKU). The company expects that the patent will be officially issued later this year, and if issued, the patent's initial 20-year term would expire in 2024. The company has a number of other pending patent applications covering various aspects of Kuvan compositions and dosing.

"We believe the issuance of this patent will be significant in strengthening our proprietary position on Kuvan," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "This patent would prevent potential competitors from using or copying Kuvan's approved dosing regimen. Based on the claims allowed by the USPTO, we believe that the once daily dosing regimen will prevent therapeutically equivalent generic competition to Kuvan while the patent is in force."

About Kuvan

Kuvan (sapropterin dihydrochloride) Tablets are indicated in the United States to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.

The active ingredient in Kuvan, sapropterin dihydrochloride, is the synthetic form of 6R-BH4 (tetrahydrobiopterin), a naturally occurring enzyme cofactor that works in conjunction with phenylalanine hydroxylase (PAH) to metabolize Phe.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of orphan e
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMarin to Present at the 4th Annual Citi Biotech Day
2. BioMarins Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
3. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
4. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Piper Jaffray Healthcare Conference
6. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces Third Quarter 2008 Financial Results
9. BioMarin Corrects Information Included in Bloomberg Article
10. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
11. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 According ... (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes ... Global Forecasts & Trends to 2018", published by MarketsandMarkets, ... in geographies such as North America ... , and the Rest of the World (RoW). ...
(Date:7/29/2014)... SPRINGS, Colo. , July 29, 2014 /PRNewswire/ ... specializing in cannabis formulation-based drug development and related ... York Times for taking a strong position in ... its Sunday, July 27, 2014 publication.  The New ... editorials and articles this week exploring the issue ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for business, and ... Center @3401 , a collaborative effort of Drexel University ... help attract and nurture start-up businesses in the region, officially ... , The Innovation Center @3401 (ic@3401), which is located at ... home of DreamIt Ventures and Point.io ...
(Date:7/29/2014)... Seattle, WA (PRWEB) July 29, 2014 ... central IRB services, has been awarded accreditation by ... (IASSC) for its Lean Six Sigma Deployment ... eliminate waste and improve performance. , Quorum’s Lean ... granted the Accredited Deployment Program designation. The designation ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3
... ... Support Innovative Start-up Companies and Entrepreneurs in Communications and Communications Convergence , ... San Diego, CA (PRWEB) June ... of Cricket Communications, Inc., a leading provider of unlimited wireless services, today announce their ...
... Germany, June 17 , - MedITEX ... Medicine , - MedITEX from 28 June ... , The IT consulting company CRITEX, which ... in vitro fertilisation, MedITEX IVF,at the 25th Annual Meeting of the ...
... 16 Microfluidic Systems, a privately-held company, announced ... "Sonication to Selectively Lyse Different Cell Types". This ... extraction of male/female DNA from a mixed forensic ... of biological sample processes for analysis and identification. ...
Cached Biology Technology:San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4New IVF Software MedITEX to be Presented at the ESHRE Exhibition 2MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis. 2
(Date:7/28/2014)... a mechanism in part of the brain that is key ... both type 1 and type 2 diabetes. The findings are ... the National Academies of Sciences . , "We,ve discovered ... of the hypothalamus known as the ventromedial nucleus sets ... in the blood," said lead author Sabrina Diano, professor in ...
(Date:7/28/2014)... Solanum pennellii , a wild relative of the domestic ... researchers including the labs headed by Professors Neelima Sinha ... Plant Biology. The new genome information may help breeders ... July 27 in the journal Nature Genetics , ... University in Germany. The UC Davis labs carried out ...
(Date:7/28/2014)... is no cure for Alzheimer,s disease and other forms ... closer to finding treatment. , University of Washington bioengineers ... the harmful changes of the body,s normal proteins into ... Alzheimer,s, Parkinson,s, heart disease, Type 2 diabetes and Lou ... they shift from their normal state into an abnormally ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... industry is being significantly challenged as production levels ... means for improving the industry,s competitiveness are being ... Manufacturing, Innovation, Trade, Resources and Energy (DMITRE) has ... to undertake a study that identifies potential routes ...
... restrictions have become unnecessarily restrictive and expensiveon Mars., ... astrobiologists Alberto Fairn of Cornell University and Dirk ... Office of Planetary Protection,s "detailed and expensive" efforts ... missions to search for life on the red ...
... Research Careers) Program has announced the travel award recipients ... in Immunology meeting in Boston, MA from July 28-August ... entry of students, postdoctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ...
Cached Biology News:Bioeconomy as a solution for South Australia's declining forest industry 2Bioeconomy as a solution for South Australia's declining forest industry 3Researchers call for rethinking efforts to prevent interplanetary contamination 2
...
... Bio-Plex maintenance, calibration, and validation ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... system holds 48 x 0.2 ml tubes, or ... independently excites fluorescence (470-500 nm) for each well, ... light (523-543 nm and 540-700 nm). The system ... Peltier heat pumps provide superb thermal performance. System ...
Biology Products: